QbD elements missing during IND/NDA filing – preventing late-stage reformulation
Addressing Missing QbD Elements in IND/NDA Filings to Prevent Late-Stage Reformulations In today’s rapidly evolving pharmaceutical landscape, ensuring a robust Quality by Design (QbD) framework during the Investigational New Drug…